Search Results
Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder
Sean Pittock, ECTRIMS 2022: Phase 3 CHAMPION-NMOSD trial results – Ravulizumab for AQP4-IgG NMOSD
Many Clinical Trials Underway For Treating Neuromyelitis Optica
Potential for Preventing NMOSD, Improving Access to Panel Testing
Dr. Sean Pittock
Autoimmune Encephalitis: Immunopathogenic Mechanisms, ... - Dr. Sean Pittock | Building Bridges 2021
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Part 1
PREVENT study: eculizumab in patients with AQP4 immunoglobin G-positive NMOSD
AQP4-IgG FACS Assay: Finding NeMO [Hot Topic]
Tips for Diagnosing Neuromyelitis Optica Spectrum Disorder
Zero Relapses in Patients With NMOSD Given Ravulizumab
Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD
![AQP4-IgG FACS Assay: Finding NeMO [Hot Topic]](https://img.youtube.com/vi/noDtkXwB-6o/hqdefault.jpg)
